ReviewCureus2025
Magnesium Sulfate in Pediatric Emergency Medicine: Pharmacology, Evidence, and Clinical Applications.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric migraine: Neurodevelopmental mechanisms, clinical phenotypes, and modern therapeutics.World journal of clinical pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnesium sulfate (MgSO₄) is a well-established therapeutic agent with extensive historical use, predominantly recognized in obstetrics. However, its critical role in pediatric emergency care remains underrecognized despite substantial clinical evidence supporting its efficacy in severe asthma exacerbations, refractory seizures, and life-threatening cardiac arrhythmias. This review aims to consolidate and critically appraise the current evidence regarding MgSO₄ pharmacologic mechanisms, clinical applications, and therapeutic impact across major pediatric emergencies, emphasizing the potential to improve morbidity and mortality outcomes through optimized utilization. A comprehensive literature synthesis was conducted, integrating mechanistic insights with clinical trial data and guideline recommendations pertaining to MgSO₄ use in pediatric seizures, status asthmaticus, and cardiac emergencies. Emerging trends, dosing strategies, safety profiles, and comparative effectiveness were analyzed to delineate best practices. MgSO₄ demonstrates distinct electrophysiological and anti-inflammatory properties, contributing to its neuroprotective, bronchodilatory, and antiarrhythmic effects in children. Rigorous clinical evidence supports MgSO₄ as a vital adjunct in refractory status epilepticus, severe asthma not responsive to first-line therapies, and torsades de pointes or certain bradyarrhythmias. Despite these benefits, substantial disparities in clinical adoption persist globally, often due to limited awareness, protocol variability, and concerns about dosing and adverse effects. MgSO₄ represents a powerful, multi-dimensional pharmacologic agent that is critically underutilized in pediatric emergency medicine. Standardized global protocols integrating MgSO₄ could markedly enhance outcomes in seizure management, critical asthma exacerbations, and cardiac arrhythmias. This synthesis advocates for reemphasizing MgSO₄ as a first-line or adjunctive intervention in relevant pediatric emergency scenarios and supports further high-quality research to refine evidence-based guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.